BCR and chronic myelogenous leukemia, BCR-ABL1 positive: An interesting approach demonstrated the feasibility of using dPCR for the amplification of relatively long amplicons, thus allowing to monitor BCR-ABL1 not on complementary DNA (cDNA) but on genomic DNA (gDNA), which might be relevant if we consider that CML leukemic stem cells hidden in the hypoxic bone marrow niche are unable to synthesize BCR-ABL1 messenger RNA (mRNA) and the corresponding fusion protein [27].